



## **OFATUMUMAB AND ZALUTUMUMAB DATA TO BE PRESENTED AT ASCO**

*Summary: Data from multiple studies will be presented at the 2010 ASCO Annual Meeting*

**Copenhagen, Denmark; May 10, 2010** – Genmab A/S (OMX: GEN) announced today that four abstracts have been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 1-8 in Chicago, Illinois. Two additional abstracts have been accepted for publication.

Ofatumumab – Poster session, June 4 from 2:00 PM to 6:00 PM CDT  
Abstract #8042 Ofatumumab Combined with CHOP in Previously Untreated Patients with Follicular Lymphoma (FL).

Ofatumumab – Poster session, June 5 from 8:00 AM to 12:00 PM CDT  
Abstract #8095 Activity of ofatumumab (O), a fully human monoclonal antibody (mAb) targeting CD20, against rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), lymphoma xenografts, and primary tumor cells derived from patients with B-cell lymphoma.

Ofatumumab – Poster session, June 7 from 2:00 PM to 6:00 PM CDT  
Abstract #6520 Chemoimmunotherapy with Ofatumumab, Fludarabine and Cyclophosphamide (O-FC) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).

Ofatumumab – Publication on-line only  
Abstract #e18525 Phase I Study of Ofatumumab in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).

Zalutumumab – Publication on-line only  
Abstract #e13102 Role of ADCC in the in vivo Anti-tumor Effects of Zalutumumab, a Human Anti-EGF Receptor Antibody.

The full abstracts will be available at [www.asco.org](http://www.asco.org) on May 20, 2010 at 6:00 PM (EDT).

Genmab will also present the following, which was accepted as a late breaking abstract:

Zalutumumab – Oral Abstract session, June 7 from 3:00 PM to 6:00 PM CDT  
Abstract #LBA5506 An Open-Label, Randomized, Phase III Trial of Zalutumumab, a Human Monoclonal EGF Receptor Antibody, Versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-Based Chemotherapy (ZALUTE).

# OFATUMUMAB AND ZALUTUMUMAB DATA TO BE PRESENTED AT ASCO

This full abstract will be available on June 5, 2010 at 8:00 AM (EDT). This abstract will also be featured at the 2010 Best of ASCO San Francisco Meeting, July 16-17, 2010.

## About ofatumumab

Ofatumumab binds specifically to both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B- to mature B-lymphocyte) and on B-cell CLL. The CD20 molecule is not shed from the cell surface and is not internalized following antibody binding.

## About zalutumumab

Zalutumumab is a novel, investigational, high-affinity, human antibody that targets the Epidermal Growth Factor receptor (EGFr), a molecule overexpressed on the surface of many cancer cells and that is a well validated target. Zalutumumab is in development to treat head and neck cancer and has received Fast Track designation from the FDA for advanced, metastatic and/or unresectable SCCHN that has progressed following standard platinum-based chemotherapy.

Under the FDA Modernization Act of 1997, Fast Track designation means that FDA will take such actions as are appropriate to expedite the development and review of the application for approval of such product. FDA may also evaluate for filing and commence review of portions of an application for approval of a Fast Track product under certain conditions.

## About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit [www.genmab.com](http://www.genmab.com).

*This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on [www.genmab.com](http://www.genmab.com). Genmab does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law.*

Genmab<sup>®</sup>; the Y-shaped Genmab logo<sup>®</sup>; HuMax<sup>®</sup>; HuMax-CD20<sup>®</sup>; HuMax-EGFr<sup>™</sup>; HuMax-IL8<sup>™</sup>; HuMax-TAC<sup>™</sup>; HuMax-HepC<sup>™</sup>; HuMax-CD38<sup>™</sup>; HuMax-CD32b<sup>™</sup>; HuMax-TF<sup>™</sup>; HuMax-Her2<sup>™</sup>; HuMax-VEGF<sup>™</sup>;

# OFATUMUMAB AND ZALUTUMUMAB DATA TO BE PRESENTED AT ASCO

HuMax-Wnt; HuMax-cMet™ and UniBody® are all trademarks of Genmab A/S. Arzerra® is a trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations  
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

###